Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Renal osteodystrophy for nonnephrologists

William G Goodman1

  • 1Division of Nephrology and the Department of Medicine, David Geffen School of Medicine at UCLA, 7-155 Factor Bldg., UCLA Medical Center, 10833 Le Conte Ave., Los Angeles, CA, 90095, USA. wgoodman@ucla.edu

Journal of Bone and Mineral Metabolism
|February 28, 2006
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Calcimimetic use in US hemodialysis facilities in first 2 years after the launch of etelcalcetide: A descriptive analysis of real-world clinical practice and outcomes.

Hemodialysis international. International Symposium on Home Hemodialysis·2021
Same author

Activation of the Calcium Receptor by Calcimimetic Agents Is Preserved Despite Modest Attenuating Effects of Hyperphosphatemia.

Journal of the American Society of Nephrology : JASN·2021
Same author

Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism.

Calcified tissue international·2017
Same author

Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial.

Hemodialysis international. International Symposium on Home Hemodialysis·2015
Same author

Cardiovascular and Renal Outcomes Trials-Is There a Difference?

The American journal of cardiology·2015
Same author

Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Circulation·2015